• TAVR $$ in Intermediate Risk; ASD From MitraClip; Industry Payments

    Interventional cardiology news to note

    European and Japanese professional groups recommend optical coherence tomography (OCT) to guide percutaneous coronary intervention in bifurcation lesions. (EuroIntervention)

    Transcatheter aortic valve replacement (TAVR) is the more economical choice in the long term among intermediate-risk patients, according to an analysis of the PARTNER 2 trial comparing the procedure to surgery. The $20,000 increase in procedural cost was offset by lower follow-up costs and a small boost in survival, the study in Circulation showed.

    Large annulus TAVR was more likely to develop prosthetic valve regurgitation with a CoreValve instead of a Sapien XT device, according to the CHOICE trial. Use of the newer CoreValve Evolut R did not lead to more regurgitation than the Sapien 3, however, according to registry data. (JACC: Cardiovascular Interventions)

    Atrial fibrillation patients not responding to pulmonary vein isolation may get rhythm control from left atrial appendage isolation and ligationwith the Lariat+ device, according to a 31-person case series from Germany reported in JACC: Clinical Electrophysiology.

    A strong predictor of good outcomes 3 months after stroke thrombectomy is a National Institute of Health Stroke Scale score improvement by more than 4 points, 24 hours after the procedure. (Journal of NeuroInterventional Surgery)

    The interatrial trans-septal puncture required for MitraClip placement led to a persistent iatrogenic atrial septal defect at 12 months among more than one in three patients, operators reported in Heart. This long-standing septal defect was in turn linked to an elevated left atrial pressure.

    After industry payments to physicians and hospitals were made publicly searchable in 2013, there was no change in the size and scope of such payments to cardiologists in 2014-2016. During this period, over $500 million was doled out to more than 30,000 cardiologists. (Circulation: Cardiovascular Quality and Outcomes)

    Source:

    Read the original article on Medpage Today:TAVR $$ in Intermediate Risk; ASD From MitraClip; Industry Payments

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details